within Pharmacolibrary.Drugs.ATC.V;

model V09DA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.01,
    adminDuration  = 600,
    adminMass      = 0.185,
    adminCount     = 1,
    Vd             = 0.00016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Technetium (99mTc) disofenin is a radiopharmaceutical agent used in hepatobiliary imaging to evaluate liver and gallbladder function. It is administered intravenously and taken up by hepatocytes, then excreted in the bile. It is approved and currently used for diagnostic imaging in nuclear medicine.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for intravenous use in adult subjects based on general radiopharmaceutical properties and available labeling information. No compartmental PK model studies or primary human PK data are available.</p><h4>References</h4><ol><li><p>Kim, M, et al., &amp; Paik, CH (1999). Evaluation of 99mTc-mercaptoacetyltriglycine-biocytin as a new hepatobiliary imaging agent in mice coinjected with bilirubin. <i>Nuclear medicine and biology</i> 26(1) 43–49. DOI:<a href=&quot;https://doi.org/10.1016/s0969-8051(98)00077-8&quot;>10.1016/s0969-8051(98)00077-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10096500/&quot;>https://pubmed.ncbi.nlm.nih.gov/10096500</a></p></li><li><p>Fraser, IA, et al., &amp; Ellison, EC (1988). Pharmacokinetic studies of DISIDA disposition. I. Animal studies. <i>European journal of nuclear medicine</i> 14(9-10) 431–435. DOI:<a href=&quot;https://doi.org/10.1007/BF00252384&quot;>10.1007/BF00252384</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3215182/&quot;>https://pubmed.ncbi.nlm.nih.gov/3215182</a></p></li><li><p>Love, JE, et al., &amp; Fabri, PJ (1988). Pharmacokinetic studies of DISIDA disposition. II. Clinical studies. <i>European journal of nuclear medicine</i> 14(9-10) 436–440. DOI:<a href=&quot;https://doi.org/10.1007/BF00252385&quot;>10.1007/BF00252385</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3215183/&quot;>https://pubmed.ncbi.nlm.nih.gov/3215183</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V09DA01;
